Abstract:BACKGROUND & OBJECTIVEChemokines are small molecule proteins that are the main mediators of cell migration. Studies indicated that chemokines could induce antitumor immune response strongly and steadily. At present, there was not antitumor therapy about chemokine BLC combined with chemotherapy. This study was designed to explore the anti-tumor effects and mechanisms of BLC-modified tumor cell vaccine combined with cisplatin.METHODSFirstly, we transfected pcDNA-BLC into murine tumor cell lines and established stable transfected tumor cell lines (Colon26 and LL/2) to express BLC. Null plasmid pcDNA3.1 (+) was also transfected into Colon 26 or LL/2 cells stably for comparison. We established mouse model with pcDNA-BLC stable transfected tumor cells (Tc), control mouse model with pcDNA3.1(+) stable transfected tumor cells (Pc), and mouse model with parental tumor cells (Nc). Then the 60 mice were inoculated subcutaneously (s.c.) in the right flanks with a total of 5x10(5) viable tumor cells (Tc to 20 mice, Pc to 20 mice, and Nc to 20 mice, respectively; 6-8 week BALB/c female mouse in colon 26 mouse model or 6-8 week C57BL/6 female mouse in LL/2 mouse model). The groups (Tc, Pc, and Nc) were randomly subdivided into Group A and Group B with 10 mice for each, resulting in Tc-A/Tc-B, Pc-A/Pc-B, and Nc-A/Nc-B, respectively. Group A (including Tc-A, Pc-A, and Nc-A) as chemotherapy group was injected (i.p.) with 0.1 ml cisplatin at the concentration of 2 mg/kg once a week for two weeks; Group B (including Tc-B, Pc-B, and Nc-B) as control with 0.1 normal saline. We further observed anti-tumor activity including the tumor growth, mice survival rate, side effects as well as tumor morphological analysis. Apoptotic cells were also determined in tumor tissues.RESULTSThe combination therapy group Tc-A showed significant anticancer activities. The tumor growth was inhibited efficiently with 3/10 mice showing complete regression in LL/2 mouse model and 1/10 mice showing complete regression in Colon 26 mouse model. The combination therapy group Tc-A showed that the survival rate of mice was 100% in the two mouse models, compared with 68% in group Tc-B in C57BL/6 mouse model and 65% in group Tc-B in Colon 26 mouse model and those in other groups. In addition, the combination therapy group Tc-A induced tumor cell apoptosis significantly.CONCLUSIONSThe therapy of BLC-modified tumor cell vaccine combined with cisplatin had significant synergistic effect against tumor. It might develop a new approach for specific immunotherapy of tumors.

Improved Therapeutic Effectiveness By Combining Recombinant Cxc Chemokine Ligand 10 With Cisplatin In Solid Tumors

Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma

Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin

Cisplatin Plus Anti-Pd-1 Antibody Enhanced Treatment Efficacy in Advanced Esophageal Squamous Cell Carcinoma.

Combination Therapy Of Vegf-Trap And Gemcitabine Results In Improved Anti-Tumor Efficacy In A Mouse Lung Cancer Model

(−)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells

Combination therapy of anti-cancer bioactive peptide with Cisplatin decreases chemotherapy dosing and toxicity to improve the quality of life in xenograft nude mice bearing human gastric cancer

Improved Therapeutic Effectiveness by Combining Liposomal Honokiol with Cisplatin in Lung Cancer Model

Xiao-Ai-Ping, a TCM Injection, Enhances the Antigrowth Effects of Cisplatin on Lewis Lung Cancer Cells Through Promoting the Infiltration and Function of CD8(+) T Lymphocytes.

Effect of Cisplatin Alone or Combined with Monoclonal Anti-Programmed Death Ligand-1 Anti-Body on Lung Adenocarcinoma Cell Line SPCA-1 and T Lymphocytes

Improved Therapeutic Effectiveness by Combining Recombinant Human RhoB with Low-dose Cisplatin in Human Lung Cancer in Nude Mice

[T-Peptide Enhances the Killing Effects of Cisplatinum on Lung Cancer].

Enhanced Antitumor and Anti-Metastasis Efficiency Via Combined Treatment with Cxcr4 Antagonist and Liposomal Doxorubicin

Integrating individual functional moieties of CXCL10 and CXCL11 into a novel chimeric chemokine leads to synergistic antitumor effects: a strategy for chemokine-based multi-target-directed cancer therapy

Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin

[Experimental Studies on Anti-Tumor Effects of BLC-modified Tumor Cell Vaccine Combined with Cisplatin].

Enhanced tumor suppression by adenoviral PTEN gene therapy combined with cisplatin chemotherapy in small-cell lung cancer

Enhancement of Cisplatin Sensitivity in Lung Cancer Xenografts by Liposome-Mediated Delivery of the Plasmid Expressing Small Hairpin RNA Targeting Survivin.

E10A, AN ADENOVIRUS CARRYING ENDOSTATIN GENE, DRAMATICALLY INCREASED THE TUMOR DRUG CONCENTRATION OF METRONOMIC CHEMOTHERAPY WITH LOW DOSE CISPLATIN IN A XENOGRAFT MOUSE MODEL FOR HEAD AND NECK SQUAMOUS CELL CARCINOMA

Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung Cancer

Suppression of Lung Cancer in Murine Model: Treated by Combination of Recombinant Human Endostsatin Adenovirus with Low-Dose Cisplatin